Therapy Areas: Inflammatory Diseases
Hoth Therapeutics granted US patent for novel exon-skipping therapy targeting allergic diseases
13 February 2026 - US biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced on Thursday that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance fo...
DifGen Pharmaceuticals' Fluorometholone Ophthalmic Suspension, 0.1% receives FDA approval
13 February 2026 - Generic pharmaceutical company DifGen Pharmaceuticals announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for Fluorometholone Ophthalm...
Devonian reports gene expression data showing Thykamine's molecular effects in MASH model
...
Arctic Therapeutics enrols first patients in Phase IIa trial of AT-004 for acne vulgaris
12 February 2026 - Arctic Therapeutics (ATx), an Iceland-based clinical-stage biopharmaceutical company, announced on Wednesday that the first patients have been enrolled in a Phase IIa randomised, do...
IP Group plc portfolio company Microbiotica reports positive Phase 1b data for MB310 in ulcerative colitis
11 February 2026 - Investment company IP Group plc (LSE: IPO) announced on Wednesday that its portfolio company Microbiotica Ltd has reported positive results from its Phase 1b first-in-human COMPOSER...
Formation Bio acquires worldwide rights to FHND5032 from CTFH
30 January 2026 - Formation Bio, an AI-native pharma company, and Chinese pharmaceutical company Jiangsu Chia Tai Feng Hai Pharmaceutical Co Ltd (CTFH) announced on Thursday that Formation Bio has acq...